• SyncroPatch 384/768PE

    APC with highest throughput on the market
  • SyncroPatch 384/768PE

    384 cells in parallel => upgradable to 768
  • SyncroPatch 384/768PE

    True HTS AND Gigaohm seals
  • SyncroPatch 384/768PE

    True internal perfusion with continuous data acquisition
  • SyncroPatch 384/768PE

    Assay flexibility via high tech

SyncroPatch 384/768PE - Patch clamp meets HTS

The SyncroPatch 384PE (upgradeable to 768PE) is a high throughput patch clamp instrument recording from up to 384 (or 768) cells simultaneously. The SyncroPatch 384/768PE is the highest throughput patch clamp instrument on the market with giga-seal data quality. The benefits the SyncroPatch 384/768PE offers include:

  • Giga-seal recordings
  • Borosilicate recording substrates
  • >85 % success rates routinely achieved
  • External & internal exchange
  • Temperature control
  • Voltage & current clamp
  • Whole-cell & perforated patch clamp
  • Single- & multihole chips, produced in-house
  • Rseries compensation
  • Unlimited compound applications due to continuous waste removal
  • Small compound volumes
  • Voltage and ligand-gated ion channels (voltage clamp maintained at all times)
  • Cell lines and stem cells
  • Validated system for CiPA
  • Powerful analysis software (automated IV plot and IC50 calculation)

The SyncroPatch 384/768PE is the first high quality, automated patch clamp system with the potential to bridge the gap between primary and secondary ion channel drug screening. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is a module which is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot, the Biomek FXP . Both hardware and software have been fully tested and validated with leading players in industrial drug development to provide optimum performance in true HTS for ion channel screening. Up to two PE-modules can be integrated into one liquid handling robot with 768 individual amplifiers, enabling 768 recording wells to be measured simultaneously. Upgrade from 384 to 768 recording sites is straightforward and can be done on a later occasion.

With up to 20,000 data points per day per module, it is the most efficient platform on the market for high quality ion channel recordings. This outstanding efficiency is primarily due to fully parallel measurements from 384 cells, the 384-channel pipettor, and an exceptionally efficient control and analysis software.

For detailed information:

Features and Specifications

Technical Specifications of the SyncroPatch 384/768PE

PE Technical specification


SyncroPatch 384/768PE: Standard Delivery Package

The SyncroPatch 384PE includes:

  • Biomek FXP with a 384-pipettor arm and gripper
  • 1-2 Patch Engine Modules (and 1-2 amplifiers) for the measurement of 384 or 786 cells in parallel
  • PatchControl 384 and DataControl 384 software suite
  • Temperature-controlled cell hotel
  • Barcode scanner
  • NPC-384 borosilicate recording plates
  • Optional 8-channel pipetting head for ACS function

Software

PatchControl 384

PatchControl 394PE

PatchControl 384 is a powerful graphical user interface for intuitive, quick and easy setup of voltage protocols and experimental parameters. As can be seen from the overview on the right, the recording wells are visualized and color-coded based on user-defined quality criteria, e.g. seal resistance, series resistance or capacitance. With one mouse click, the view switches to online analysis results, for example I/V curves or concentration-response curves



DataControl 384: The Analysis Software

DataControl 384 is used to visualize and analyze the PatchControl 384-data, employing user-defined data analysis templates. Results (automated IC50, EC50, IV relationship plot generation), compound information, and quality control parameters are exported together in a user-defined export format, automatically generating pdf-reports, and preparing the data for further database integration. This process is straightforward, intuitive and quickly accomplished.

Consumables

NPC-384

NPC 384

The NPC-384 chip is a proprietary innovative product by Nanion Technologies, developed for the SyncroPatch 384/768PE. It is produced and quality-assured in-house at Nanion headquarters and shipped from Munich to our international customers. Different types of NPC-384 chips are available which should be chosen depending on cell size and application.


Material
The borosilicate glass slide with the patch aperture is encased in a 384 well plate forming wells where the cells and external solutions are delivered. The design of the chip allows perfusion of the internal solution during an experiment.
Features

Each NPC-384 chip contains 384 recording chambers. These sites can be used all at one time or single rows can be used. One chip can be measured on the SyncroPatch 384PE, 2 chips on the SyncroPatch 768PE in parallel. The recordings can be performed without user intervention. Additionally, the number of exchanges of either the internal or the external solution is unlimited.


Available chip types
  • "NPC-384, 1x medium resistance": One hole per well (Order # 221102)
  • "NPC-384, 1x medium resistance plus": One hole per well (Order # 221104)
  • "NPC-384, 4x medium resistance": 4 holes per well (Order # 221402)
  • "NPC-384, 8x medium resistance": 8 holes per well (Order # 221802)
  • "NPC-384, 9x medium resistance": 9 holes per well (Order # 221902)
  • "NPC-384, 1x high resistance": One hole per well (Order # 221101)
  • "NPC-384, 4x high resistance": 4 holes per well (Order # 221401)
  • "NPC-384, 8x high resistance": 8 holes per well (Order # 221801)
  • "NPC-384, 9x high resistance": 9 holes per well (Order # 221901)
  • "NPC-384, 1x low resistance": One hole per well (Order # 221103)
  • "NPC-384, 4x low resistance": 4 holes per well (Order # 221403)
  • Buffers and Solutions

    Buffers and Solutions for the SyncroPatch 384/ 768PE

    The buffers and solutions for the SyncroPatch 384/ 768PE are produced by an external partner, quality-assured in-house at Nanion headquarters and shipped from Munich to our international customers.


    Available buffers and solutions
    • "External Solution, 500 mL, standard": (Order # 083001)
    • "Internal Solution, 500 mL": Channel specific, to be specified by the customer (Order # 083002)
    • "Reagent Kit 10 L standard": 4x 500 mL Internal Solution (channel specific, to be specified by the customer); 12 x 500 mL Standard External Solution (Order # 082102)
    • "Reagent Kit 2.5 L standard": 1x 500 mL Internal Solution (channel specific, to be specified by the customer); 4 x 500 mL Standard External Solution (Order # 082101)

    SyncroPatch 384/768PE and CiPA

    CiPA - Comprehensive In Vitro Proarrhythmia Assay

    Nanion, a committee member of the Health and Environmental Science Institute (HESI) cardiac safety and HTS teams, has a long-standing interest and extensive experience in automated patch clamp screening of cardiac ion channels. Furthermore, label-free impedance and extracellular field potential recordings of stem cell-derived cardiomyocytes (SC-CMs) is also available in our portfolio. Our instruments are used for safety screening by major pharmaceutical companies and CROs worldwide and we are happy to assist you in setting up your CiPA assays. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative aims to replace the preclinical hERG current assay required under the ICH S7B safety pharmacology guidelines and clinical TQT study, which provides a surrogate marker of Proarrhythmia, with more translationally relevant assessments of proarrhythmic risk (Sager et al., 2014). CiPA will achieve this by evaluating proarrhythmic risk of evolving drug candidates based on an understanding of the electrophysiologic mechanisms responsible for proarrhythmia linked to Torsades de pointes (TdP) and QT prolongation. The three components of CiPA include voltage clamp assessment of human ion channels, in silico reconstruction of electrophysiologic activity and confirmation using in vitro assays on human SC-CMs.


    Recommended Readings on the Role of the SyncroPatch 384/768PE in the CiPA study

    Cardiomyocytes - "Combining automated patch clamp, impedance and EFP of hiPSC-CMs"

    Icon CE   CardioExcyte 96   icon sp96   SyncroPatch 3984PE   icon pl   Patchliner Application Note 
    Cells kindly provided by Takara-Clonetech.

    Cardiac Ion Channels - "Simultaneous Assessment of CiPA Stipulated Ion Channels on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.3 MB)
    Cells were kindly provided by Charles River.

    Cardiac Ion Channels - "High Throughput Screening of Cardiac Ion Channels"

    icon sp96   SyncroPatch 384PE   icon pl   Patchliner   Icon CE   CardioExcyte 96 application note   logo pdf   (0.2 MB)

    2017 - Automated Patch Clamp Recordings of Human Stem Cell- Derived Cardiomyocytes.

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE book chapter in Stem Cell-Derived Models in Toxicology (2017)

    2015 - "High Throughput Automated Patch Clamp of Ion Channels Important in Cardiac Safety and Drug Discovery"

    icon sp96  SyncroPatch 384PE poster, Chantest Meeting 2015   logo pdf   (1.9 MB)

    2015 - "Complementary automated patch clamp, extracellular field potential and impedance recordings of iPSCs: safety screening tool box for the future"

    icon pl   Patchliner and   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE poster,   SPS 2015   logo pdf   (2.7 MB)

    Data and Applications

    Acetylcholine Receptor Alpha 3 Beta 4 - Activation

    a3b4

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Shown is a raw current response of a HEK293 cell expressing AChR (α3β4) to exposure to 300 μM nicotine. Solutions were  stacked (layered) in the pipette to achieve brief exposure times.

     

    Acetylcholine Receptor Alpha 7 - Dose Response Curve

    AChRCRCicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Galantos Pharma GmbH.

    Increasing acetylcholine concentrations (30 µM, 100 µM and 300 µM) were added to the same cell using a stacked applications protocol. 

     

    AMPA Receptor (GluR2) - Current Traces

    GluA2 repetitive CRCicon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by University of Sussex.

    Using a stacked solutions approach and a fast pipetting speed shortens the solution exchange rate and minimizes the ligand exposure time. This procedure allows for reproducible recordings of fast desensitizing ligand-gated receptors such as glutamate receptors. Here, repetitive activation of GluA2 receptors is shown. Receptors were activated with 100 µM Na-Glutamate for 3 times resulting in inward currents of similar peak amplitudes (A and B). The current onset time was approximately 10 ms (D). Panel C displays an example of a cumulative concentration response curve for Na-Glutamate (in mM: 0.1, 0.3 and 1).

    CaV1.2 - Current Voltage Relationship

    Cav12 IV

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Shown are raw current traces (top) and the constructed peak current-voltage relationship (bottom) of CaV1.2 (HEK293) recorded on the SyncroPatch 96.

     

     

     

     

     

    CaV1.2 - Stable recording from frozen stock cells

    icon sp96   170922 CaV1.2 Data SyncroPatch384PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hCaV1.2β2/α2δ1 current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Measured on the SyncroPatch 384PE using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 100 %. The cells were used from a frozen cell stock (after induction) and recorded stably for more than 20 minutes. The IC50 value of Nifedipine was determined as 21 nM.

    Erythrocytes - Analyzing Primary Cells

    Erysicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Dr. Andrea Brüggemann.

    Shown is a current recording from an erythrocytes as a response to a voltage ramp from -100 mV to +100 mV aquired on the SyncroPatch 96. The increase in current was induced by a reduction in osmoliarity.

     

    GABAA Receptor - Modulator Diazepam

    Diazepam

     icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Shown is a raw current response of a HEK293 cell expressing GABAA receptors to initial exposure to GABA, followed by joint exposure to GABA and diazepam (as indicated). Solutions were  stacked (layered) in the pipette to achieve brief exposure times.

    GABAA Receptor (a1b2g2) - On-set of response

    Gaba and close up bea

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    With the SyncroPatch 96 currents can be recorded continuously during compound application. This, in conjunction with a solution exchange time of about 100 ms, makes the SyncroPatch 96 an excellent tool for investigations of ligand gated ion channels. In the data example, 10 μM GABA was added to a HEK293 cell expressing GABAA (α1β2γ2) receptors. The boxed trace shows a close up of the GABA-response.

    GABAA Receptor (a1b3g2) - Antagonists

    GABAa1 Antagonists

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Pharmacology on GABAA α1β3γ2 as recorded on a multihole (4x) plate. Mean concentration response curves for Bicuculline, IC50 = 470 nM (n = 14); for a5IA IC50 = 461.19 pM (n = 9), maximum block was 29% at 100 nM; for FG7142 IC50= 54.52 nM (n = 15), maximum block was 58% at 10 μM; for MRK016 maximum current inhibition was 44.8% at 1 uM, IC50= 5.98 nM (n = 11). 

    GABAA Receptor (a1b3g2) - Bicuculline Dose Response

    GABAa1 Bicuc DR vert

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Pharmacology on GABAA α1β3γ2 as recorded on a multihole (4x) plate. Raw data traces of one exemplary recording using control solution (A) and increasing Bicuculline concentrations and a subsequent  washout (B). Cells were held at a constant holding potential of -70 mV and GABA was applied for approximately 2 s. After 3 control applications of 3 μM GABA, increasing concentrations of inhibitors were applied. Cells were preincubated with antagonists before co-applicaiton with GABA. 

    GABAA Receptor (a1b3g2) - Success Rates

    Seal Stat GABAa1

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Statistic of hGABAA a1b3g2 cells recorded on one NPC-96 1-hole (1x) patch clamp chip. Cslow = 18.8 ±1.6 (n=32), Rs = 8.6 ± 1.5 (n=32). 41.66 % of the cells on one NPC-96 chip (total n=96) had seal resistance > 1 GOhm at the beginning and at the end of experiment. 63.4 % of the cells had a seal resistance above 500 MOhm, which remained stable throughout the experiment.

     

     

    GABAA Receptor (a5b3g2) - Antagonists

    GABAa5 Antagonists small

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Mean concentration response curves for Bicuculline, IC50 = 327 nM (n = 14); for a5IA IC50 = 933 pM (n = 11),  maximum block was 45% at 100 nM; for FG7142 IC50= 2.5 mM (n = 9), maximum block was 64.3% at 10 μM; for MRK016 maximum current inhibition was 52% at 1uM, IC50= 1.02 nM (n = 15).

    GABAA Receptor (a5b3g2) - Dose Response

    GABAa5 ver

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Pharmacology on GABAA α5β3γ2 as recorded on the SyncroPatch96. Raw data traces of one exemplary cell using increasing GABA concentrations (A) or increasing Bicuculline concentrations and a subsequent washout (B).

     

     

     

    GABAA Receptor (a5b3g2) - Success Rates

    Bar Seal cm Rs GABAa5AppNote

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Statistic of hGABAA α5β3γ2 cells recorded on one NPC-96 patch clamp chip. Cslow = 26.2 ±1.8 (n=32), Rs = 4.1 ± 0.2 (n=32). 53 % of the cells on one NPC-96 chip (total n=96) had seal resistance > 1 Giga Ohm at the beginning, 47 % at the end of experiment. 76 % of cells reached a seal resistance above 500 MΩ, which remained constant throughout the experiment.

     

     

     

    Glycine Receptor (GlyRa1) - Reproducible Current Recordings

    Glycine 384 raw OA reproducibleicon sp96   SyncroPatch 384PE data and applications:

    Glycine-mediated current traces and corresponding time plots from 384 simultaneously recorded HEK cells are shown. Multiple additions of 50 µM Glycine produce very robust current responses with similar peaks, providing best conditions for cumulative pharmacology on one cell.

    hERG - Current Voltage Relationship

    HergIV No and with Leak

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Cytomyx Millipore.

    Borosilicate glass chips are used as the patch clamp substrate, ensuring excellent voltage control of the cell membrane and high quality seals. Voltage gated channels such as hERG (expressed in HEK293) have been used to validate the system. These traces show the raw current responses of a single cell to a hERG IV pulse protocol. The data were recorded on the SyncroPatch 96. In the upper screenshot raw current traces are shown. In the lower one the same current traces after leak subtraction are shown.

     

     

    hERG - Stable Recordings with Accurate Pharmacology

    Syncro hERG 2icon sp96   SyncroPatch 384PE data and applications: 
    Cells were kindly provided by Charles River Laboratories.

    Current-voltage relationship of hERG (Kv11.1) expressed in HEK293 is shown along with pharmacology of 4 hERG-active compounds. The current-voltage relationships for all 384 wells (top) using perforated patch (Escin) and multi-hole chips (4 holes per well) are shown. In all 384 wells, a hERG-mediated current was observed with peak amplitude >700 pA at -20 mV. Using a pharmacology voltage protocol, experiments were stable lasting over 20 minutes. Concentration response curves for astemizole, pimozide, cisapride and terfenadine revealed IC50 values consistent with those found in the literature. 

    KV1.3 - Internal Perfusion

    p41 1 IntPerficon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    The SyncroPatch 96 supports internal perfusion allowing internal administration of compounds, second messengers and metabolites. Here, KV1.3 currents, endogenously expressed in Jurkat cells, were blocked by the internal administration of Cs+ followed by washout with Cs+-free internal solution.

    KV1.3 - Pharmacology with High Success Rate

    Kv13 384 raw onl norm Quini 2icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by Evotec.

    Shown are screenshots of a pharmacology experiment performed with the SyncroPatch 384PE. Recordings from 384 KV1.3 expressing CHO cells were performed simultaneously. Original current traces and the peak current over time are displayed. Data are analysed with DataControl384 full analysis tool. With just a few mouse-clicks normalized concentration response curves can be generated. Here, normalized response and the IC50 of Quinidine is shown. Darkening shades of blue indicate increasing compound concentration.

    KV1.5 - Dose response curve of 4-AP

    icon sp96   KV1.5 Data 3845PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing a dose-response curve of 4-AP on KV1.5 stably transfected cells. Measured on the SyncroPatch 384PE using multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 100%. The IC50 value of 160 µM measured on the SyncroPatch 384PE corresponds well to literature (IC50 4-AP: 270 µM; Gutman et al., Pharmacological Reviews 57: 473-508, 2005). 

    KV4.3/KChIP2 - Dose-response curve

    icon sp96   170922 KV4.3 Data SyncroPatch384PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3/KChIP2 current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Using whole cell mode in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE. The IC50 value of flecanaide was determined as 28.3 µM which is in accordance to literature. The success rate of valuable data for the analysis was 100%. 

    KV7.1 (KVLQT) - Dose-response curve

    icon sp96   170922 KV7.1 Data SyncroPatch384PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV7.1/KCNE (KVLQT/minK) current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Using the perforated patch methodology (Escin) in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE. The IC50 value of Chromanol 293B was determined as 3.82 µM. The success rate of valuable data for the analysis was 100%. 

    NaV1.5 - Analyzing iPSC-derived Cardiomyocytes

    0NavLidocaineScreenicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly supplied by Cellular Dynamics.

    Inhibition of NaV1.5 currents in stem cell-derived cardiomyocytes (iCells) by lidocaine. Lidocaine concentrations: 6 µM, 62 µM and 620 µM. The obatined  IC50 -value was 14 µM.

     

    NaV1.5 - Blind Study using an Inactivation Protocol

    NaInactivation

    icon sp96   SyncroPatch data (a predecessor model of SyncroPatch 384PE) and applications:

    22 selected compounds were tested in a blind study on the SyncroPatch 96 using HEK 293 cells expressing hNav1.5 ion channels. The IC50-values were compared to manual patch clamp measurements, performed at the customer site.

    NaV1.5 - Current Voltage Relationship

    NaStrom IV

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Borosilicate glass chips are used as the patch clamp substrate, ensuring excellent voltage clamp of the cell membrane and high quality seals. Voltage gated channels such as hNaV1.5 (HEK293) have been used to validate the system. This data example shows the I/V characteristics and the corresponding raw current traces of a single cell from a recording on the SyncroPatch 96.

     

     

    NaV1.5 - Inactivation Protocol

    NaInactivation

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Cytomyx Millipore.

    Shown are raw current responses of HEK293 cells expressing hNaV1.5 to a double (inactivation) pulse protocol.

     

    NaV1.5 - Lidocaine Dose Response

    NaLidocaine

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Cytomyx Millipore

    Timecourse of the NaV1.5 peak currents in response to exposure to different lidocaine concentrations (0 μM, 1 μM, 10 μM, 100 μM, 0 μM). Time points at which the external solution was exchanged is marked by the red lines.

    NaV1.7 - Accurate Voltage Clamp

    SyncroPatch 384PE Nav17 CHO Anaxon 384 raw IV 2

     icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by Anaxon AG.

    CHO cells expressing NaV1.7 were used on the SyncroPatch 384PE with a success rate of > 90% for cells which have a seal resistance > 500 MΩ (see inset). A screenshot of the PatchControl 384 software showing current traces in response to a voltage step protocol and the corresponding current-voltage plot.

    NaV1.7 - Success Rate & Access Resistance

    SuccessRate Nav17 Rs Cm Syncroicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    The cells were kindly supplied by Millipore.

    A Success rate (seal resistance) of ND7-23 cells on the SyncroPatch 96. Shown is a bar graph of seal resistances on the SyncroPatch 96 at the start (blue) and end (grey) of the experiment.
    B Bar graph of cell capacitance (Cslow) of ND7-23 cells. Mean Cslow = 19.9 ± 0.8 pF (n = 75 ). 
    C Bar graph of series resistance (Rs) values for ND7-23 cells on the SyncroPatch 96. Mean Rs = 9.1 ± 1.3 MΩ (n = 75).

    NaV1.8 - Automated Analysis

    DC96 overview CRCResults Nav18icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by EMD Millipore.

    With the SyncroPatch Analysis Tool - DataControl96, IC50 plots are easily generated, displayed, averaged, evaluated, and modified.
    Here, Lidocaine concentration response curves (CRC) of rNaV1.8 expressing ND7-23 cells are shown.

    NaV1.8 - Block by Lidocaine

    Lido traces ConcResponseicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    A Raw traces from an exemplar cell recorded on the SyncroPatch 96 showing inhibition of current by increasing concentrations of lidocaine. Shown are current responses to a single step protocol to 20 mV for 25 ms from a holding potential of -120 mV.
    B Average concentration response curve for lidocaine, IC50 = 178 ± 11 μM (n = 35).

    NaV1.8 - Block by Tetracaine

    Tet traces Conc responseicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    A Raw traces from an exemplar cell recorded on the SyncroPatch 96 showing inhibition of current by increasing concentrations of tetracaine. Shown are current responses to a single step protocol to 20 mV for 25 ms from a holding potential of -120 mV.
    B Average concentration response curve for tetracaine, IC50 = 71 ± 5 μM (n = 40).

    NaV1.8 - I/V Characteristics

    ND723 Nav18 Syncro IV Figureicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications: 

    The ND7-23 cells were kindly provided by Millipore.

    A Raw traces from an exemplar cell recorded on the SyncroPatch 96. Shown are current responses to increasing voltage steps from -60 to +60 mV.
    B Average current-voltage plot, Vhalf of activation was 12 mV (n = 32).
    C Average inactivation plot, Vhalf of inactivation was -27 mV (n = 32). Nav1.8 currents started to activate at about -30 mV, peak response was elicited between 20 and 30 mV and Vhalf of activation was 12 mV. The Vhalf of inactivation was -27 mV in good agreement with the literature.

    NaV1.8 - Success Rate & Access Resistance

    SuccessRate Seal cm Rs ND723 Syncroicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    The cells were kindly supplied by Millipore.

    A Success rate (seal resistance) of ND7-23 cells on the SyncroPatch 96. Shown is a bar graph of seal resistances on the SyncroPatch 96 at the start (blue) and end (grey) of the experiment.
    B Bar graph of cell capacitance (Cslow) of ND7-23 cells. Mean Cslow = 22.6 ± 0.8 pF (n = 88 ).
    C Bar graph of series resistance (Rs) values for ND7-23 cells on the SyncroPatch 96. Mean Rs = 7.1 ± 0.4 MΩ (n = 88). 

     

    NMDA NR1/NR2A - Activation and Modulation

    NMDA 384well view

    icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by B'Sys.

    Here, activation and modulation of the NR1/NR2A subunit containing NMDA receptors are shown. Currents were evoked by application of 10 µM Glutamate in the presence of 10 µM Glycine.

    Application of the neurosteroid Pregnenolone sulfate (PS) potentiates the current response induced by Glutamate. The potency of PS was analysed in a single-point screen. The EC50 of PS (39.6 µM), comprising 74% of the cells is nicely corresponding to litereature values (Irwin, et al. Neurosci. Lett. 1992)

    P2X2/ P2X3 - Application of ATP

    P2X23 10uATPicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications: 
    Cells were kindly supplied by Evotec AG, Hamburg, Germany

    Shown are three consecutive current responses of 1321 N1 cells expressing P2X2 / P2X3 receptors to 10 µM ATP. Cells were washed twice between compound applications (holding −80 mV). The data demonstrate the reproducability of the whole cell current responses.

    TRPV1 - Activation by Internal Application of Capsaicin

    0TRPV1 Internal Acticon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    The SyncroPatch 96 allows continues recording during the application of compounds from the intracellular side. Here, TRPV1 channels were activated by the internal application of capsaicin.

       

     

     

     

    TRPV1 - Application of Capsaicin

    TRPV1 bea verzerrticon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Using the SyncroPatch 96 CHO cells expressing TRPV1 were subjected to a voltage ramp (-100 mV to +100 mV) in the presence and absence (control) of 2 μM capsaicin. As shown in the exemplar traces, inward and outward currents increase upon capsaicin addition.

    Webinars

    03.11.2016 | External Webinar: Accelerating Ion Channel Characterization and New Drug Candidate Identification

    icon sp96   SyncroPatch 384PE

    This webinar will show high-throughput functional annotation of human ion channel variants associated with excitation disorders will be described along with use of the Syncropatch 384PE to measure subtype selective activation of KV7 potassium channels as well as inhibition of voltage gated sodium channels like NaV1.7, NaV1.1, and NaV1.5.
    Organisation: Icagen Inc.

    07.06.2016 | External Webinar: A new analysis capability to improve assessment of cardiac liability in high throughput electrophysiology

    icon sp96   SyncroPatch 384PE

    AstraZeneca has implemented the Nanion SyncroPatch 384PE electrophysiology platform. This webinar will show how AstraZeneca and Genedata developed a processing and analysis pipeline for the complex data, reading binary raw data directly from the instrument into Genedata Screener.
    Organisation: Genedata AG.

    28.07.2015 | Webinar: High Throughput and High Fidelity: Automated Patch Clamp in Screening and Research

    icon sp96   SyncroPatch 384PE and   icon pl   Patchliner 

    The webinar covers the use of the Patchliner and the SyncroPatch 384/768PE for characterization of ion channels and screening of ion channel active compounds.

    24.10.2013 | Webinar: SyncroPatch 384PE - the PatchEngine. Superior Ion Channel Drug Screening

    icon sp96   SyncroPatch 384PE

    The Webinar covers the introduction of the SyncroPatch 384PE and its features.

    07.03.2013 | Webinar: Top gear ion channel screening

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE)

    This Webinar covers the general setup of the and features of this automated patch clamp device.

    Downloads:

    Application Notes

    ASIC3 - "Activation and Inhibition of human ASIC3 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (1.7 MB)
    Cells were kindly provided by Millipore.  

    Cardiac Ion Channels - "High Throughput Screening of Cardiac Ion Channels"

    icon sp96   SyncroPatch 384PE   icon pl   Patchliner   Icon CE   CardioExcyte 96 application note   logo pdf   (0.2 MB)

    Cardiac Ion Channels - "Simultaneous Assessment of CiPA Stipulated Ion Channels on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.3 MB)
    Cells were kindly provided by Charles River.

    Cardiomyocytes - "Combining automated patch clamp, impedance and EFP of hiPSC-CMs"

    Icon CE   CardioExcyte 96   icon sp96   SyncroPatch 3984PE   icon pl   Patchliner Application Note 
    Cells kindly provided by Takara-Clonetech.

    CaV1.2 - "High Throughput Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (2.7 MB)
    Cells were kindly provided by SB Drug Discovery.  

    CaV1.2 - "Stability and Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (5.3 MB)
    Cells were kidly provided by Charles River.

    CaV1.3 - "Characterization of CaV1.3 on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.5 MB)

    CaV3.2 - "High Throughput Pharmacology of CaV3.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.  

    CFTR - "Different modes of activation of CFTR recorded on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (5.7 MB)

    GABAA a1b3g2 - "Characterization of hGABAA α1β3γ2 on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.5 MB)
    Cells were kibndly provided by Millipore.

    GABAA a5b3g2 - "Characterization of hGABAA α5β3γ2 on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.5 MB)
    Cells were kindly provided by Millipore.

    hERG - "High Throughput Pharmacology of hERG Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (0.6 MB)

    NaV1.5 - "High Throughput Pharmacology of NaV1.5 Channels on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.9 MB)
    Cells were kindly provided by Millipore.

    NaV1.7 - "Characterization of hNaV1.7 on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (0.7 MB)
    Cells were kindly provided by Anaxon.

    NaV1.7 - "Pharmacology on rNaV1.7 performed on Nanion‘s SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.

    NaV1.8 - "Characterization of rNaV1.8 (ND7-23) on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.7 MB)
    Cells were kindly provided by Millipore.

    NaV1.8 - "Stability and reproducibility of hNaV1.8 recordings on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.4 MB)
    Cells were kindly provided by Charles River.

    NMDA Receptors (NR1/NR2A & NR1/NR2B) - "Activation and Inhibition of human NMDA Channels on Nanion`s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (3.0 MB)
    Cells were kindly provided by Charles River.

    TMEM16A (ANO1) - "Internal perfusion of Ca2+ to activate TMEM16A/ANO1 on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (6.8 MB)
    Cells were kindly provided by SB Drug Discovery.

    TREK-1 - "Activation and inhibition of TREK-1 on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (6.0 MB)
    Cells were kindly provided by SB Drug Discivery.

    TRPA1 - "High Throughput Activation and Block of hTRPA1 on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.

    TRPC5 - "Internal perfusion of Ca2+ to activate hTRPC5 on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.7 MB)
    Cells were kindly provided by Charles River.

    Publications

    2017 - Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions

    icon sp96  SyncroPatch 768PE publication in Nature Communications (2017)

    2017 - High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE

    icon sp96  SyncroPatch 768PE publication in PLoS One (2017)

    2017 - Automated Patch Clamp Recordings of Human Stem Cell- Derived Cardiomyocytes.

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE book chapter in Stem Cell-Derived Models in Toxicology (2017)

    2016 - Use-dependent Block of Human Cardiac Sodium Channels by GS967

    icon sp96  SyncroPatch 384PE publication in Molecular Pharmacology (2016)

    2016 - Safety pharmacology studies using EFP and impedance

    Icon CE  CardioExcyte 96 publication in Journal of Pharmacological and Toxicological Methods (2016)

    2016 - pH-sensitive K+ channel TREK-1 is a novel target in pancreatic cancer

    icon sp96  SyncroPatch 384PE publication in Biochimica et Biophysica Acta (2016)

    2016 - Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module

    icon sp96  SyncroPatch 384PE publication in Journal of Lab Automation (2016)

    2015 - Novel screening techniques for ion channel targeting drugs

    icon pl  Patchliner,   icon sp96   SyncroPatch 384PE and   Icon CE   CardioExcyte 96 publication in Channels (2015)

    2015 - Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp

    icon sp96  SyncroPatch 384PE publication in BCM Pharmacology and Toxicology (2015)

    2014 - New strategies in ion channel screening for drug discovery: are there ways to improve its productivity?

    icon sp96  SyncroPatch 384PE publication in Journal of Laboratory Automation (2014)

    2014 - Early identification of hERG liability in drug discovery programs by automated patch clamp

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE publication in Frontiers in Pharmacology (2014)

    2012 - Natural and artificial ion channels for biosensing platforms

    icon pap   Port-a-Patch,   icon pl   Patchliner,   icon sp96   SyncroPatch 96 ((a predecessor model of SyncroPatch 384PE) and   icon vpp   Vesicle Prep Pro publication in Analytical and Bioanalytical Chemistry (2012)

    2012 - HTS techniques for patch clamp-based ion channel screening - economy and advances

    icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Expert Opinion on Drug Discovery (2012)

    2011 - State-of-the-art automated patch clamp devices: heat activation, action potentials, and high throughput in ion channel screening

    icon pap   Port-a-Patch,   icon pl  Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Frontiers in Pharmacology (2011)

    2011 - Automated electrophysiology makes the pace for cardiac ion channel safety screening

    icon pl  Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Frontiers in Pharmacology (2011)

    2010 - Renaissance of ion channel research and drug discovery by patch clamp automation

    icon pap  Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE)  publication in Future Medical Chemistry (2010)

    Product Sheets

    SyncroPatch 384PE - Product Sheet

    icon sp96   SyncroPatch 384/768PE product sheet:   logo pdf   (1 MB)

    SyncroPatch 384PE Product Flyer - "Patch clamp finally goes HTS"

    icon sp96   SyncroPatch 384PE product flyer:   logo pdf   (0.5 MB)

    Posters

    2015 - "Complementary automated patch clamp, extracellular field potential and impedance recordings of iPSCs: safety screening tool box for the future"

    icon pl   Patchliner and   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE poster,   SPS 2015   logo pdf   (2.7 MB)

    2015 - "High Throughput Automated Patch Clamp of Ion Channels Important in Cardiac Safety and Drug Discovery"

    icon sp96  SyncroPatch 384PE poster, Chantest Meeting 2015   logo pdf   (1.9 MB)

    2015 - "Organellar Transporters and Ion Channels - How to access their electrophysiology by using the SURFE2R technology and Planar Patch Clamp"

    Icon N1   SURFE²R N1 and   icon sp96   SyncroPatch 96 (a predecessor model of the SyncroPatch 384PE) and   icon pap   Port-a-Patch poster, GRC - Organellar Channels and Transporters 2015   logo pdf   (1.6 MB)

    2015 - "The backstage pass to study your favorite TRP channel"

    icon pap   Port-a-Patch and   icon pl   Patchliner and SyncroPatch 384PE and   icon sp96   SyncroPatch 384PE poster, TRP Meeting 2015   logo pdf   (2.2 MB)

    2016 - Next level toxicity screening: From single channel to overall cell behavior

    Icon Orbit Mini   Orbit mini,   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE poster, Meeting of the French Society of Toxinology (SFET) 2015  logo pdf   (0.9 MB)

    Contact Us

    Please type your full name.
    Invalid email address.
    Invalid Input
    Invalid Input
    Nanion Technologies GmbH

    Ganghoferstr. 70A
    D-80339 Munich - Germany
    info@nanion.de